Clinical Trial Update: Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updates reported results for bevacizumab with Abraxane in recurrent epithelial ovarian cancer and primary peritoneal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Accelerated Community Oncology Research Network | Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2012-04-05